What Exelixis (EXEL) Said on Its Q3 Earnings Call
Published . Updated .
This report does not map to a usual set of affected companies.
Directly affected
- EXEL Exelixis+23.4% 13d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Exelixis belongs to, so it often moves with news about it.
- AMGN Amgen+18.4% 30d
Amgen is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.6% 30d
Gilead Sciences is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+28.2% 30d
Moderna is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-17.4% 17d
argenx SE is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Exelixis in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| EXEL | -2.63% | -1.39% | base | +4.71% | +5.76% | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| AMGNNo price data for this ticker | — | — | — | — | — | — | — |
| GILDNo price data for this ticker | — | — | — | — | — | — | — |
| MRNANo price data for this ticker | — | — | — | — | — | — | — |
| ARGXNo price data for this ticker | — | — | — | — | — | — | — |
| RVMDNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
What Exelixis (EXEL) Said on Its Q3 Earnings Call Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| EXEL | that day | +4.71% | final price |
| EXEL | the next day | +5.76% | final price |
| EXEL | three days earlier | -1.39% | final price |
| EXEL | five days earlier | -2.63% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 38 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 65 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 79 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 81 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 63 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “What Exelixis (EXEL) Said on Its Q3 Earnings Call” looks
12 out of 100
“What Exelixis (EXEL) Said on Its Q3 Earnings Call” scores 12 out of 100. The score uses 1 sources.